Marisa A Kollmeier

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10028, USA
    BJU Int 111:1231-6. 2013
  2. doi A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Brachytherapy 11:271-6. 2012
  3. ncbi Brachytherapy for clinically localized prostate cancer: optimal patient selection
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Arch Esp Urol 64:847-57. 2011
  4. ncbi Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy
    M A Kollmeier
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Urol 173:808-12. 2005
  5. doi What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Marisa A Kollmeier
    Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1275 York Avenue, New York, NY 10021, USA
    Nat Clin Pract Urol 5:584-5. 2008
  6. doi Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer
    Sarah A Milgrom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 130:436-40. 2013
  7. doi Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer
    Rupesh Kotecha
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Brachytherapy 12:44-9. 2013
  8. doi Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy
    Neil B Desai
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 131:604-8. 2013
  9. ncbi A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer
    Daniel E Spratt
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Brachytherapy 12:428-33. 2013
  10. ncbi Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality
    Marisa A Kollmeier
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 57:645-53. 2003

Collaborators

Detail Information

Publications25

  1. doi Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10028, USA
    BJU Int 111:1231-6. 2013
    ..To report long-term outcomes of men ≤60 years treated with brachytherapy (BT) for low- and intermediate-risk prostate cancer...
  2. doi A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Brachytherapy 11:271-6. 2012
    ..To compare biochemical outcomes and morbidity associated with iodine-125 ((125)I) and palladium-103 ((103)Pd) brachytherapy as part of combined modality therapy for clinically localized prostate cancer...
  3. ncbi Brachytherapy for clinically localized prostate cancer: optimal patient selection
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Arch Esp Urol 64:847-57. 2011
    ..Careful selection of appropriate patients for these therapies, however, is critical for optimizing both disease-related outcomes and treatment-related toxicity...
  4. ncbi Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy
    M A Kollmeier
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Urol 173:808-12. 2005
    ..We analyzed the risk of urinary morbidity and incontinence in patients undergoing transurethral resection of the prostate (TURP) following prostate brachytherapy...
  5. doi What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Marisa A Kollmeier
    Memorial Sloan Kettering Cancer Center, Department of Radiation Oncology, 1275 York Avenue, New York, NY 10021, USA
    Nat Clin Pract Urol 5:584-5. 2008
    ..How these results should best be incorporated into dose-escalated radiotherapeutic approaches remains unclear, however, and this issue requires further investigation...
  6. doi Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer
    Sarah A Milgrom
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 130:436-40. 2013
    ..One regimen is concurrent external beam pelvic irradiation (RT) and cisplatin, then carboplatin/paclitaxel. This study reports an institutional experience using this approach in stage III (FIGO 2009) endometrial cancer...
  7. doi Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer
    Rupesh Kotecha
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Brachytherapy 12:44-9. 2013
    ....
  8. doi Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy
    Neil B Desai
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 131:604-8. 2013
    ..To evaluate patterns of relapse in early stage uterine papillary carcinoma (UPSC) patients receiving adjuvant intravaginal radiotherapy (IVRT) with or without chemotherapy...
  9. ncbi A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer
    Daniel E Spratt
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Brachytherapy 12:428-33. 2013
    ..Much of the justification for its adoption was derived from earlier clinical results using high-dose-rate (HDR) brachytherapy. We determine whether HDR's dosimetry can be achieved by virtual SBRT...
  10. ncbi Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality
    Marisa A Kollmeier
    Department of Radiation Oncology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 57:645-53. 2003
    ..Patients treated during the first 6 years of the program were analyzed to determine the value of patient selection and implant quality on biochemical control...
  11. doi Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 75:1350-6. 2009
    ..To report the influence of posttreatment prostate-specific antigen (PSA) nadir response at 2 years after external beam radiotherapy (RT) on distant metastases (DM) and cause-specific mortality (CSM)...
  12. doi Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer
    Karin K Shih
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 128:535-9. 2013
    ..The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with or without chemotherapy in high-risk endometrial cancer...
  13. ncbi Combined modality treatment in the management of high-risk prostate cancer
    Richard G Stock
    Department of Radiation Oncology, Mount Sinai School of Medicine, Box 1236, 1184 5th Avenue, New York, NY 10029, USA
    Int J Radiat Oncol Biol Phys 59:1352-9. 2004
    ....
  14. doi Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy
    Nadeem Riaz
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 84:707-11. 2012
    ..To investigate the utility of endorectal coil magenetic resonance imaging (eMRI) in predicting biochemical relapse in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy...
  15. doi Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation
    Karin K Shih
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Gynecol Oncol 128:540-3. 2013
    ..The purpose of this study was to determine the incidence of PIF and assess prognostic factors, including intensity-modulated RT (IMRT), in gynecologic oncology patients treated with postoperative pelvic RT...
  16. doi Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer
    Michael R Folkert
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Gynecol Oncol 128:288-93. 2013
    ..The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with concurrent chemotherapy in intermediate- and high-risk early stage cervical cancer...
  17. doi Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer
    Daniel E Spratt
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Radiat Oncol Biol Phys 85:686-92. 2013
    ..To report long-term survival and toxicity outcomes with the use of high-dose intensity modulated radiation therapy (IMRT) to 86.4 Gy for patients with localized prostate cancer...
  18. pmc Less-restrictive, patient-specific radiation safety precautions can be safely prescribed after permanent seed implantation
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Brachytherapy 9:101-11. 2010
    ..To use radiation exposure rate measurements to determine patient-specific radiation safety instructions with the aim of reducing unnecessary precaution times and to evaluate potential doses to members of the public...
  19. doi How to select the optimal therapy for early-stage prostate cancer
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Crit Rev Oncol Hematol 83:225-34. 2012
    ..This review will discuss the relevant issues in the decision making and treatment selection for the patient...
  20. doi Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 79:713-8. 2011
    ..To investigate the association between 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and biochemical and survival outcomes after high-dose radiotherapy (RT) for prostate cancer...
  21. doi A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy
    Yoshiya Yamada
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY Electronic address
    Brachytherapy 13:111-6. 2014
    ..We report the toxicity and biochemical tumor control outcome of a prospective Phase II study using high-dose-rate brachytherapy (HDR) alone as a salvage therapy for recurrent disease after external beam radiotherapy (EBRT)...
  22. doi How to select the optimal therapy for early-stage prostate cancer
    Marisa A Kollmeier
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Crit Rev Oncol Hematol 84:e6-e15. 2012
    ..This review will discuss the relevant issues in the decision making and treatment selection for the patient...
  23. doi Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 53:1172-9. 2008
    ..To report the long-term tumor control and survival outcomes after conformal external-beam radiotherapy for patients with clinical stage T3 prostate cancer...
  24. ncbi Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer
    Maura Miccò
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States Electronic address
    Eur J Radiol 83:1169-76. 2014
    ....
  25. doi Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer
    Ana P Kiess
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 127:321-5. 2012
    ..The purpose of this study is to report our single-institution experience with concurrent adjuvant intravaginal radiation (IVRT) and carboplatin/paclitaxel chemotherapy for early stage uterine papillary serous carcinoma (UPSC)...